New pill targets deadly brain tumor in patients with rare gene fusion
NCT ID NCT06105619
First seen Jan 31, 2026 · Last updated May 13, 2026 · Updated 16 times
Summary
This study tests a new drug called vebreltinib for people with a certain type of recurrent brain cancer (glioblastoma) that has a specific gene change (ZM fusion). About 84 participants will either receive vebreltinib capsules or standard chemotherapy. The main goal is to see if the new drug helps people live longer and is safe to take.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital,Capital Medical University
Beijing, Beijing Municipality, 100070, China
Conditions
Explore the condition pages connected to this study.